您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > Fosravuconazole L-lysine ethanolate
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Fosravuconazole L-lysine ethanolate
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Fosravuconazole L-lysine ethanolate图片
CAS NO:914361-45-8
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate)，Ravuconazole 的前药，是一种具有口服活性的广谱抗真菌剂。Fosravuconazole L-lysine ethanolate 可用于念珠菌病，灰指甲病和寄生虫病的研究。
Cas No.914361-45-8
别名磷酸咪康唑L-赖氨酸乙醇,BMS-379224 L-lysine ethanolate; E-1224 L-lysine ethanolate
分子式C31H40F2N7O8PS
分子量739.73
溶解度DMSO : 50 mg/mL (67.59 mM; Need ultrasonic)|Water :< 0.1 mg/mL (ultrasonic) (insoluble)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a prodrug of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research[1][2][3].

Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus, and Trichophyton species[1].

Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain[3].

[1]. Shinichi Watanabe, et al. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018 Oct;45(10):1151-1159.
[2]. Katsura Hata, et al. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. Parasitol Int. 2020 Dec 25;81:102278.
[3]. LÍvia de Figueiredo Diniz, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018 May 25;62(6):e00401-18.